Introduction
Patients with systemic lupus erythematosus (SLE) remain at increased risk for premature death [1] , particularly among young adults [2] . Up to 45% of cases present early end organ damage, related to persistent activity or kidney disease [3] . Renal involvement, which occurs in 40 to 50% of patients in most series, is associated with mortality rates approximately eight times higher than expected [2] , and remains only partially responsive to the best available treatments. Indeed, therapy with cyclophosphamide has not improved patient survival compared with corticosteroids [4] , and the largest controlled trial comparing mycophenolate mofetil with intravenous cyclophosphamide in lupus nephritis achieved complete remission in only 8.6% and 8.1% of patients, respectively [5] . Undoubtedly there is a need for safer and more eff ective treatments for SLE.
Mesenchymal stem cells
Mesenchymal stromal cells, originally described in the 1960s as bone forming cells in the bone marrow [6] , are now called multipotent mesenchymal stromal cells, or more commonly mesenchymal stem cells (MSCs) since they display adult stem cell multipotency. Th us, they diff erentiate into bone, cartilage and other connective tissues [7] . Unlike hematopoietic stem cells, which originate from bone marrow, MSCs can also be isolated from a variety of other tissues, such as umbilical cord or adipose tissue, and can be extensively expanded in vitro by up to 50 cell doublings without diff erentiation [8] . While these properties initially put MSCs center stage of an alleged era of regenerative medicine, the unexpected fi ndings of Bartholomew and colleagues in 2002 [9] pointed to new features of these progenitor cells, the consequences of which are still being revealed in several areas of medicine. MSCs were found to escape T-cell recognition, suppress T-cell response to mitogens and also to prolong skin graft survival in baboons. In spite of a wide array of immunomodulatory eff ects that were subsequently proven to aff ect T and B lymphocytes, natural killer and antigen-presenting cells [10, 11] , MSCs remain hypoimmunogenic since they express low levels of major histocompatibility (MHC) class I molecules and do not express MHC class II or co-stimulatory (CD40, CD40L, CD80 or CD86) molecules [12] . Since the eff ects on immunocompetent cells are not MHC restricted, allogenic MSCs are widely used with no need to match them with host human leukocyte antigens (HLAs). Th e mechanisms underlying these eff ects are a subject of great scientifi c interest, as reviewed elsewhere in this issue, but apparently involve both cell contact and soluble
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Flavio A Carrion 1,2 and Fernando E Figueroa* 1,2 factors, including indoleamine 2,3-dioxygenase, prostaglandin E2, nitric oxide, transforming growth factor (TGF)-β1, IL-10, soluble HLA-G, and IL-1 receptor antago nists [13, 14] . Also, several growth factors, such as hepatocyte growth factor, vascular endothelial growth factor (VEGF), insulin-like growth factor, epidermal growth factor, basic fi broblast growth factor and stromal cell-derived factor-1, among others, have been implicated in the modulatory and reparative eff ects of MSCs [15] .
Recently, several studies have identifi ed critical roles for microRNAs (miRNAs) involved in proliferation, migration and diff erentiation of MSCs, suggesting that they might play an important role in the acquisition of reparative MSC phenotypes [16] .
Therapeutic use of MSCs in autoimmune and infl ammatory diseases
Given their vast proliferative potential, extensive immunosuppressive properties, and also the ease of access to proper tissue sources, therapies with autologous or allogenic MSCs have been tested in a variety of immunemediated disease models, including experimental allergic encephalomyelitis [17, 18] -a model of multiple sclerosisdiabetic NOD/SCID mice [19] , collagen-induced arthritis [20, 21] , and several lupus murine models [22] [23] [24] [25] [26] [27] [28] . Results have been mainly encouraging, but not altogether consistent, particularly in the case of arthritis [29] , and lupus mice [26, 27] .
At the time of writing this review, 141 registered human trials on MSCs were found at the National Institutes of Health ClinicalTrials.gov website [30] , including 13 for graft versus host disease (GVHD), 10 for diabetes, 7 for Crohn's disease or ulcerative colitis, 5 for multiple sclerosis, 2 for amyotrophic lateral sclerosis, one each for Sjögren syndrome and systemic sclerosis and two for SLE. Some of these trials point to non-immune-mediated conditions that are associated with tissue injury, such as hepatic cirrhosis, myocardial infarction or congestive heart failure. In several instances it has become apparent that MSCs are not necessarily replacing diseased tissues or diff erentiating into separate cell lineages, but seem to exert a complex pattern of trophic, regenerative and antiinfl ammatory eff ects [31, 32] .
In humans, the most studied application for MSCs is GVHD, a complication of hematopoietic stem cell transplan tation in which donor T cells attack an immunocompromised and genetically disparate recipient [33] . In 2004, Le Blanc and colleagues [34] treated a 9-year-old boy with severe treatment-resistant acute GVHD of the gut and liver with third party haplo-identical motherderived MSCs. Clinical response was striking, with improvement of liver and intestinal function. Th e most recent placebo controlled trials confi rmed the signifi cant improvement in liver and gastrointestinal GVHD, but did not reach signifi cance for durable complete responses or other primary endpoints [35] .
Mesenchymal stem cells in systemic lupus erythematosus
Perhaps the most remarkable results for human MSC therapy are now emerging from the latest clinical trials in severe, treatment-refractory SLE [36, 37] . While these are still small, uncontrolled and non-multicentric studies, the recent reports of successful MSC treatment in other infl ammatory and scarring conditions that are typical of the SLE spectrum [38, 39] lend support to these notoriously favorable outcomes. Th ese trials also highlight the need to advance the clinical science of stem cell therapy and underscore the challenge of identifying specifi c mechanisms of action, given the multi-tiered eff ects of cellular therapies in vivo [40] .
While in the past the connective tissue was assigned a low rank among organized tissues, nowadays it seems to harbor far reaching properties. Undoubtedly, when Dr Paul Klemperer suggested that the histopathological connective tissue changes found in SLE were common to the 'obscure maladies that collectively are called diseases of the connective tissue or collagen diseases' [41] , little did he know that a cure for such diseases might also be found within connective tissues!
Animal models of disease
While the MSCs derived from SLE patients and diseased mice are still immunosupressive in vitro [42] , they are abnormal in terms of phenotype, proliferation and diff erentiation [43] [44] [45] . Sun and colleagues have forwarded the hypothesis that an impaired bone marrow MSC niche contributes to disease development in human [43] and murine SLE [23] . Th ey describe in Fas-defi cient MLR/lpr mice a signifi cant osteoporosis phenotype with osteoclast activity and T cell over-activation that does not respond to cyclophosphamide treatment, but is corrected by MSC transplant [23] . Even if this assumed MSC defi ciency is only a consequence of immune activation in SLE, this rationale has supported the use of allo-or xenogeneicinstead of autologous -MSCs for the treatment of SLE [23] . For example, in MRL/lpr mice, allogenic mouse or human MSCs derived from bone marrow (BM-MSCs), umbilical cord (UC-MSCs) or exfoliated deciduous teeth have all been highly eff ective in reducing or even normalizing serum autoantibodies, proteinuria, renal pathology and survival of diseased animals [22] [23] [24] [25] . In contrast, the NZB/W F1 strain, considered the murine model that most closely resembles human SLE, has shown diverging results. For example, human UC-MSCs delayed disease and alleviated lupus nephritis [27] , while allogenic murine BM-MSCs (from C57BL/6J mice) did not aff ect proteinuria or double-stranded DNA (dsDNA) levels, but still improved renal function [28] . Surprisingly, BM-MSCs from another strain (BALB/c mice) had opposite eff ects, enhancing anti-dsDNA antibody pro duction and worsening disease and kidney pathology [26] .
Human systemic lupus erythematosus
Prompted by the positive results in the Fas-defi cient MRL/lpr mice treated with human MSCs from healthy individuals [22] , Sun and colleagues [23] treated four patients with active disease and lupus nephritis (24 hour urine protein ≥1 g and/or serum creatinine ≥1.5 mg/dl) that was unresponsive to monthly intravenous cyclophos phamide (0.75 g/m 2 ) and oral prednisone (≥20 mg/ day) for 6 months. All patients received one infusion of ≥1 × 10 6 BM-MSCs (from healthy family members) per kilogram of body weight. Th e Systemic Lupus Disease Activity Index (SLEDAI) at 1, 6 and 12 months follow-up improved signifi cantly, as did urinary protein, and also CD4+ Foxp3+ T regulatory (Treg) cell counts at 3 months follow-up. Prednisone and cyclophosphamide were reduced, and the latter even suspended in two patients. None had complications after 12 to 18 months follow-up. Th ese encouraging results led to a larger phase I open trial in 15 patients -including the fi rst 4 cases reportedwith refractory disease as described above, except that one-third of patients had also failed oral mycophenolate mophetil (1 to 2 g/day for 3 months) [37] . All cases fulfi lled the previously stated criteria for refractory renal disease except one with only refractory thrombo cytopenia (24 × 10 9 /L). Non-renal manifesta tions included arthritis, severe skin disease, serositis and ten cases with non-responsive cytopenias. Patients received one intravenous infusion of 1 × 10 6 allogeneic BM-MSCs per kilogram body weight (harvested from passages 3 to 5) from non-HLA-matched healthy family members. Subsequently, steroids were reduced to 5 to 10 mg/day maintain ing lower dose cyclophosphamide (0.4 to 0.6 g) for 2 to 3 months. Mean follow-up reached 17.2 (3 to 36) months with no adverse eff ects, deaths or ensuing GVHD. Clinical and serological changes were quite dramatic for this group of patients with severe disease as gauged by an average baseline SLEDAI of 12.1 ± 3.3, in spite of daily prednisone (23 ± 5 mg) and immunosuppressive drugs. In 12 patients SLEDAI again improved signifi cantly, to 3.2 ± 2.8 at 12 months (P < 0.05), remaining under 8 in all patients and even zero in four patients. Only one subject was able to discontinue immunosuppressants, remaining with inactive disease at 12 months on 5 mg daily prednisone. Two patients fl ared at 6 and 12 months, respectively. Quite surprisingly, 24 hour proteinuria (2,538.0 ± 382.3 mg at baseline) decreased signifi cantly (1,430.7 ± 306.3; P < 0.01, n = 12) as soon as one week after MSC therapy -even preceding changes in anti-dsDNA antibodies -and continued to improve thereafter until month 12. Glomerular fi ltration rate improved in two patients who had reduced values at study entry, as did creatinine levels in four subjects. Anti-dsDNA antibodies decreased signifi cantly at 1 month (P < 0.05) and 3 months (P < 0.05) post-transplant. Treg cells, which have been found to be quantitatively and qualitatively defi cient in active SLE [46, 47] , were restored at week 1 (from 2.56 ± 0.37 to 4.58 ± 0.51; P < 0.05, n = 13) as judged by the percentage of CD4+ Foxp3+ cells among peripheral blood mononuclear cells.
A second open trial from this group in Nanjing, China followed, reporting the use of UC-MSCs in severe lupus [36] . UC-MSCs are easily accessible, have high proliferative potential [48] and have been used with success in lupus mice [24] . Patients (n = 16) and entry criteria were similar to the previous study, though this time 5 of 15 renal cases had histological confi rmation of proliferative nephritis, and 11 were preconditioned with cyclophospha mide (0.8 to 1.8 g intravenously) prior to MSC infusion. Subsequently, prednisone was reduced to 5 to 10 mg every 2 weeks and patients were kept on maintenance cyclophosphamide (0.6 to 0.8 g), which was able to be eventually discontinued in only three individuals. Mean follow-up was only 8.25 months. Signifi cant improve ment at 1 and/or 3 months was verifi ed by SLEDAI score (two patients completed 2 years with scores <4), serum albumin, 24 hour urinary protein, serum creatinine (six patients), serum C3 (fi ve patients) and anti-dsDNA antibodies. Baseline CD4+ Foxp3+ cells (Treg cells) increased signifi cantly at 3 and 6 months, and a fall in serum IL-4 (with a non-signifi cant increase of IFN-γ) was interpreted by the authors as indicative of improvement of pathogenic Th 2 imbalance, though animal lupus models have shown the opposite cytokine change [27] . Finally, a case report from the group in Nanjing, but not from the realm of renal disease, draws further attention to the potency of MSC treatment: a 19-year-old girl with a recent diagnosis of SLE presented with massive diff use alveolar hemorrhage unresponsive to methylprednisolone (160 mg/d for 4 days, 500 mg/d for 3 days) and intravenous immunoglobulin (20 g/day for 5 days) [49] . Repeated high-resolution chest computed tomography spanning 9 weeks showed diff use bilateral alveolar infi ltrates. After only one day of UC-MSC infusion (2 × 10 6 /kg body weight) the patient's level of oxygen saturation rose from 71 to 91%, and 5 days later mechanical respiratory support was removed. Nine days later high-resolution chest computed tomography showed complete resolution. Recurrent pulmonary disease 6 weeks after being discharged -while on prednisone, cyclophosphamide and cyclosporin A -again responded promptly to MSC retreatment. Th is dramatic case underscores the need to unravel the biological components underlying the clinical eff ects of MSCs.
Mechanisms of the therapeutic eff ects of MSC treatment
Despite the in vitro and in vivo evidence for a therapeutic eff ect of MSCs in SLE, the mechanisms by which MSCs exert their immunomodulatory and reparative eff ects are still incompletely understood, but most likely involve multiple mechanisms (Figure 1 ).
Proinfl ammatory 'licensing' of MSCs
In contrast to therapies that cause global immune suppression, MSCs have been dubbed 'smart' immune modulators since their suppressive eff ects require a previous 'licensing' step that occurs in the presence of an infl ammatory environment, and is mediated by the secretion of specifi c cytokines [50] . Th us, IFN-γ, alone or together with tumor necrosis factor-α, IL-1α or IL-1β, are required to provoke the expression by MSCs of high levels of soluble factors involved in immunosuppression, such as indoleamine 2,3-dioxygenase, hepatocyte growth factor, TGF-β1 and nitric oxide [51] [52] [53] [54] . Th e need for this activation step has been confi rmed in a model of GVHD since recipients of IFN-γ -/-T cells did not respond to MSC treatment evolving into fatal GVHD [55] .
Tipping of the Th1/Th2 balance
Although still controversial, an imbalance in IFN-γ and IL-4 cytokine levels, suggestive of a pathogenic T helper 2 (Th 2) response, has been reported in SLE. Accordingly,
Figure 1. Systemic administration of mesenchymal stem cells can trigger distal (endocrine) or local (paracrine) eff ects that include
cell-mediated actions. 1) Promotion of angiogenesis: vascular endothelial growth factor (VEGF), insulin like growth factor 1 (IGF-1), monocyte chemoatractant protein 1 (MCP-1), basic fi broblast growth factor (bFGF) and interleukin 6 (IL-6). 2) Stem cell growth and diff erentiation: stem cell factor (SCF), leukemia-inhibitory factor (LIF), macrophage colony-stimulating factor (M-CSF), stromal derived factor 1 (SDF-1), angiopoietin 1 and activin A. 3) Inhibition of fi brosis: hepatocyte growth factor (HGF), bFGF, adrenomedullin (ADM). 4) Inhibition of apoptosis: VEGF, HGF, IGF-1, transforming growth factor (TGF)-β, bFGF, granulocyte macrophage colony-stimulating factor (GM-CSF), activin A and thrombospondin-1. Immune mediated eff ects include the following (5 to 8). experimental data suggest that MSC therapy might ameliorate SLE by promoting the conversion from a Th 2 humoral response to a Th 1 cellular immune response through modulation of IL-4 and IFN-γ levels in eff ector T cells. Zhou and colleagues [22] showed that intraperito neal infusion of human BM-MSCs in MRL/lpr mice decreased the production of IL-4 and increased IFN-γ in peripheral blood T cells. Sun and colleagues [36] reported similar fi ndings with UC-MSC transplantation in patients with refractory SLE 3 months after treatment, also suggesting a polarization toward a Th 1 phenotype that was associated with clinical improvement. However, Aggarwal and Pittenger [51] showed the opposite eff ect with the addition of human MSCs to diff erentiated eff ector T cells in vitro, and Chang and colleagues [27] found that UC-MSC transplantation in NZB/W F 1 mice was associated with an increase in the Th 2 phenotype in the face of improving disease. Th e divergent results from these studies underline the complexity of both MSCmediated eff ects and the immunopathogenesis of SLE.
Eff ects on CD4+ T cell populations: upregulation of Treg/Th17 ratio
Several studies have provided evidence of a quantitative and/or qualitative defect of Treg cells in human SLE, as well as an increased production of Th 17 proinfl ammatory cells [46] [47] 56] . On the other hand, MSCs have been shown to induce the generation of functional Treg cells both in vitro and in vivo [21, 57, 58] . In MLR/lpr mice, the transplantation of MSCs from many sources (bone marrow, umbilical cord or exfoliated deciduous teeth), can restore Treg cells and induce a signifi cant reduction in Th 17 levels, consequently up-regulating the ratio of Treg/Th 17 cells [23] [24] [25] . In human SLE, the transplantation of either allogeneic or autologous MSCs derived from bone marrow or umbilical cord also increases Treg cells, suggesting that this may be one of the mechanisms of the MSC-mediated improvement of disease [23, 36, 37] . However, in two patients with active but not highly infl ammatory SLE, we reported that the infusion of autologous MSCs induced no amelioration in spite of generating a marked increase in Treg cells [59] .
Mesenchymal stem cell homing and diff erentiation
Long-term persistence of autologous or allogenic MSCs after a single intravenous infusion has been described in baboons, with levels of tissue engraftment ranging from 0.1 to 2.7% [60] . However, in a chronic kidney disease model, only repeated injections were associated with functional improvement and cortical entrapment of MSCs at 5 weeks [39] . In NZB/W F1 lupus mice treated with 1 × 10 6 human UC-MSCs via the tail vein, Chang and colleagues [27] could evidence MSCs in kidney tissues at week 2 of infusion, but no long-term engraftment.
Even if MSCs protect and improve recovery from several models of acute and chronic renal injury [61, 62] , paracrine and endocrine eff ects seem most important, since con ditioned medium from MSCs has been able to mimic the benefi cial eff ects of stem cell therapy [63] . Th e intricacy of such endocrine factors in vivo has been elegantly illustrated by Lee and colleagues [64] in a mouse model in which the reduced size of myocardial infarction in response to the infusion of human MSCs was due to the secretion of the anti-infl ammatory protein TSG-6 triggered by MSC entrapment in the lung.
Gene expression and growth factors
A number of genes and growth factors responsible for renal regeneration also seem to be involved in renal repair after the administration of MSCs [38] . High levels of angiogenic factors, such as VEGF, have been related to glomerulonephritis in SLE [65, 66] , and Zhou and colleagues [22] showed that transplantation of human BM-MSCs in MRL/lpr mice reduced the expression of VEGF and TGF-β and also deposits of fi bronectin in glomeruli. In an ischemic model of chronic kidney disease we have shown that a single intravenous infusion of autologous MSCs triggers a signifi cant increase in a group of nephrogenic proteins and transcription factors related to endothelial (VEGF and the angiopoietin-1 receptor Tie-2) and epithelial (bone morphogenetic protein-7, Pax-2, and basic fi broblast growth factor) diff er entiation, in association with a marked improvement of renal function [67] . Additionally, the importance of epigenetic regulatory factors in the control of biological processes and of the immune response has also been stressed. Common miRNA patterns of expression have been found in three diff erent murine models of SLE [68] , suggesting these might be targeted therapeutically. Since MSCs have been shown to secrete microparticles enriched in miRNAs [69] , several authors have suggested that microvesiclemediated transfer of mRNA from MSCs to target tissues might also participate in some of the processes involved in immunoregulation or in the recovery from kidney injury in response to stem cell treatment [70] .
Conclusion
Th e results of the fi rst clinical trials with MSC therapy in severe SLE are undoubtedly encouraging. However, the heterogeneity of MSCs as defi ned today and the intricate circuitry of cellular and humoral factors that mediate their presently known eff ects still point to many issues to be resolved in order to pave the way for cell therapy in SLE. Long-term safety concerns remain an issue, given the description of in vitro malignant MSC transformation [71] and the unknown interaction of regular immunosupressants with single or repeated MSC therapy [72] .
Along with the need for larger randomized controlled clinical trials, future advances from stem cell science can be expected to pinpoint signifi cant MSC subpopulations and/or stem cell markers for regenerative or immunoregulatory properties, as well as specifi c mechanisms of action [73] . Th us, assays for in vitro or in vivo MSC potency could be developed, leading the way to the use of more potent stimulated or primed pre-treated MSCs.
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